AUNA Stock Forecast 2025-2026
Distance to AUNA Price Targets
AUNA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Auna (AUNA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AUNA and similar high-potential opportunities.
Latest AUNA Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, AUNA has a bullish consensus with a median price target of $12.75 (ranging from $9.00 to $19.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $6.97, the median forecast implies a 82.9% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AUNA Analyst Ratings
AUNA Price Target Range
Latest AUNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AUNA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 11, 2025 | JP Morgan | Joseph Giordano | Overweight | Maintains | $13.50 |
| Sep 20, 2024 | JP Morgan | Joseph Giordano | Overweight | Maintains | $13.00 |
| Aug 20, 2024 | JP Morgan | Joseph Giordano | Overweight | Maintains | $14.00 |
| Apr 23, 2024 | HSBC | Raj Sinha | Buy | Initiates | $12.60 |
| Apr 16, 2024 | Citigroup | Leandro Bastos | Buy | Initiates | $14.00 |
| Apr 16, 2024 | JP Morgan | Joseph Giordano | Overweight | Initiates | $16.00 |
| Apr 16, 2024 | Morgan Stanley | Mauricio Cepeda | Overweight | Initiates | $14.00 |
Auna S.A. (AUNA) Competitors
The following stocks are similar to Auna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Auna S.A. (AUNA) Financial Data
Auna S.A. has a market capitalization of $515.87M with a P/E ratio of 16.2x. The company generates $1.19B in trailing twelve-month revenue with a 2.5% profit margin.
Revenue growth is +4.1% quarter-over-quarter, while maintaining an operating margin of +17.9% and return on equity of +7.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Auna S.A. (AUNA) Business Model
About Auna S.A.
Provides high-quality healthcare services in Latin America.
Auna S.A. operates a network of hospitals, clinics, and outpatient centers, generating revenue through a range of medical services, including general medicine and specialized treatments. The company focuses on leveraging advanced medical technology and a commitment to patient care, ensuring high standards of service delivery.
Auna S.A. emphasizes innovation and sustainability in healthcare, aiming to enhance accessibility and quality of care in the region. Its strategic positioning and commitment to healthcare advancements make it a significant player in the Latin American healthcare market.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
14,605
CEO
Mr. Jesús Antonio Zamora Leon
Country
Luxembourg
IPO Year
2024
Website
www.aunainvestors.comAuna S.A. (AUNA) Latest News & Analysis
Latest News
Auna S.A. (NYSE: AUNA) filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the SEC on April 10, 2025. The report is available on the SEC's website.
Auna S.A.'s filing of its Annual Report provides transparency on financial performance, aiding in assessing investment potential and compliance with regulatory requirements.
Auna reported 11% revenue and 20% EBITDA growth for 2024, fueled by operations in Peru and expansion in Mexico. It aims for a leverage ratio under 3X by 2025 amid regulatory challenges in Colombia.
Auna's strong revenue and EBITDA growth, strategic expansion in Mexico, and focus on deleveraging signal financial health and potential for increased investor confidence.
Auna S.A. (AUNA) and Coya Therapeutics, Inc. (COYA) performance is being compared to their sector's performance in 2023, indicating potential relative strength or weakness.
Performance comparisons indicate how Auna S.A. and Coya Therapeutics are faring against their peers, providing insights into potential investment opportunities or risks within their sectors.
Auna (NYSE: AUNA) reported its fourth quarter and full-year financial results for 2024, with results presented in Peruvian Soles and compliant with IFRS standards.
Auna's Q4 and FY24 financial results reveal its performance in a key emerging market. Strong results could indicate growth potential, impacting stock valuation and investor sentiment.
Auna S.A. has signed a five-year exclusive agreement with Opción Oncología, enhancing its position in the oncology sector in Mexico.
Auna's exclusive agreement with a top oncology clinic enhances its market position in healthcare, potentially driving revenue growth and improving investor confidence in its future performance.
Auna S.A. (AUNA) and BioMarin Pharmaceutical (BMRN) have been compared to their sector's performance for the year to date. Further details on performance metrics were not provided.
Performance comparisons indicate how Auna S.A. and BioMarin Pharmaceutical are faring relative to peers, influencing investor sentiment and potential stock valuation.
Frequently Asked Questions About AUNA Stock
What is Auna S.A.'s (AUNA) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Auna S.A. (AUNA) has a median price target of $12.75. The highest price target is $19.00 and the lowest is $9.00.
Is AUNA stock a good investment in 2025?
According to current analyst ratings, AUNA has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AUNA stock?
Wall Street analysts predict AUNA stock could reach $12.75 in the next 12 months. This represents a 82.9% increase from the current price of $6.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Auna S.A.'s business model?
Auna S.A. operates a network of hospitals, clinics, and outpatient centers, generating revenue through a range of medical services, including general medicine and specialized treatments. The company focuses on leveraging advanced medical technology and a commitment to patient care, ensuring high standards of service delivery.
What is the highest forecasted price for AUNA Auna S.A.?
The highest price target for AUNA is $19.00 from at , which represents a 172.6% increase from the current price of $6.97.
What is the lowest forecasted price for AUNA Auna S.A.?
The lowest price target for AUNA is $9.00 from at , which represents a 29.1% increase from the current price of $6.97.
What is the overall AUNA consensus from analysts for Auna S.A.?
The overall analyst consensus for AUNA is bullish. Out of 4 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.75.
How accurate are AUNA stock price projections?
Stock price projections, including those for Auna S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.